Short Interest in Sysmex Corporation ADR (OTCMKTS:SSMXY) Increases By 601.3%

Sysmex Corporation ADR (OTCMKTS:SSMXY) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 277,294 shares, an increase of 601.3% from the December 15th total of 39,540 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 670,805 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily trading volume, of 670,805 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.0% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group raised shares of Sysmex from a “hold” rating to a “buy” rating in a report on Thursday, October 9th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

Sysmex Trading Up 0.9%

Shares of SSMXY stock opened at $10.19 on Tuesday. Sysmex has a 1 year low of $9.00 and a 1 year high of $20.31. The firm has a market capitalization of $6.41 billion, a PE ratio of 20.38 and a beta of 1.13. The stock has a fifty day moving average of $9.85 and a two-hundred day moving average of $12.48. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.49 and a current ratio of 3.34.

Sysmex (OTCMKTS:SSMXY) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.16 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.16. The business had revenue of $826.60 million for the quarter, compared to analysts’ expectations of $880.80 million. Sysmex had a net margin of 9.32% and a return on equity of 9.86%. As a group, research analysts expect that Sysmex will post 0.57 EPS for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.